(Q45753674)

15 December 2017

title

CSF biomarkers in different phenotypes of Parkinson disease (English)

1 reference

15 December 2017

1 reference

1 reference

Kurt A Jellinger

1

1 reference

15 December 2017

publication date

8 November 2011

1 reference

15 December 2017

Journal of Neural Transmission

published in

1 reference

15 December 2017

volume

119

1 reference

15 December 2017

issue

4

1 reference

15 December 2017

page(s)

455-456

1 reference

15 December 2017

https://scigraph.springernature.com/pub.10.1007/s00702-011-0736-0

exact match

0 references

cites work

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Biomarkers for early detection of Alzheimer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

The neuropathologic basis of different clinical subgroups of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Biomarkers in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0736-0

Neurochemical biomarkers in the differential diagnosis of movement disorders

21 January 2018

1 reference

12 December 2020

CSF tau markers are correlated with hippocampal volume in Alzheimer's disease.

1 reference

12 December 2020

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.

1 reference

12 December 2020

CSF markers of neurodegeneration in Parkinson's disease

1 reference

12 December 2020

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

1 reference

12 December 2020

10.1007/S00702-011-0736-0

Identifiers

DOI

1 reference

15 December 2017

Dimensions Publication ID

0 references

1 reference

15 December 2017